Pharmafile Logo
Pharmafocus logo
Advanced Search

NHS

Showing 15 posts of 1107 posts found.

top_10_image

Top Ten most popular articles on Pharmafile.com this week!

May 10, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, GSK, Innoviva, NHS, Novartis, health, migraine, pharma

This week was a particularly bad one for the NHS after it was revealed thousands of EU nurses were leaving …

News
genentech_web

Ocrevus becomes first NICE-approved therapy on the NHS for primary progressive multiple sclerosis

May 9, 2019
Sales and Marketing Genentech, NHS, NICE, Ocrevus, UK

NICE has announced its final appraisal decision on Genentech’s Ocrevus (ocrelizumab), choosing to recommend the drug for use on the …

News

Thousands of EU nurses and midwives leave NHS because of Brexit

May 9, 2019
Medical Communications NHS, health, hospitals, midwifes, nurses

Nearly 5,000 EU nurses and midwifes have left the NHS over the past two years. The number of EU nationals …

News

Number of GPs in decline for first time in 50 years

May 8, 2019
Manufacturing and Production, Research and Development GP, NHS, pharma, public health

The number of GPs has been in decline, year on year, since 2014. The decline marks the first sustained fall …

News

Will mobile phones save the NHS?

May 7, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, UK, feature, mhealth, mobile health, pharma

The NHS is sick. According to politicians and NHS chiefs, the cure involves a strong dose of mHealth. Louis Goss …

Feature

Two thirds of MPs believe NHS should spend less on medicines

April 30, 2019
Manufacturing and Production Long Term Plan, MPs, NHS, UK, government, health, public health

Nearly two thirds (64%) of MPs believe the NHS should direct more resources towards prevention, over funding for new treatments, …

News

The price of access: Can the NHS afford Orkambi?

April 29, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Drug pricing, NHS, NICE, Orkambi, UK, Vertex, access, cystic fibrosis, feature, pharma, pricing

The impasse over access to Vertex’s Orkambi for cystic fibrosis patients in England and Wales has revealed the cracks in …

Feature

NICE recommends Akcea’s Tegsedi for rare, life-threatening progressive disease

April 17, 2019
Research and Development, Sales and Marketing Akcea, NHS, NICE, Tegsedi, UK

Akcea Therapeutics has shared the news that Tegsedi (inotersen), its antisense oligonucleotide (ASO) inhibitor of human transthyretin (TTR) production, has …

News

Half of patients have sub-optimal response to statins, research shows

April 16, 2019
Manufacturing and Production NHS, NICE, NICE guidelines, cholesterol, health, statins

Around half of patients who are prescribed statins do not see their cholesterol drop to desired levels within two years, …

News
28246711066_52e38bc591_z

NHS Confederation chief says news of Brexit extension is a relief

April 12, 2019
EU, NHS, UK, brexit, health, medicine

Niall Dickson, the Chief Executive of the NHS Confederation, has said news of the decision to extend the Brexit deadline …

News
novartis_window

Novartis’ Kisqali combo rejected by NICE for advanced breast cancer

April 11, 2019
Sales and Marketing Kisqali, NHS, NICE, Novartis, pharma

Novartis’ Kisqali (ribociclib) has been rejected for use on the NHS by NICE for the treatment of advanced breast cancer, …

News

Eisai and MSD’s Lenvima recommended for NHS Scotland in advanced or unresectable liver cancer

April 8, 2019
Manufacturing and Production, Sales and Marketing Cancer, NHS, Scotland, Scottish Medicines Consortium, UK, liver cancer, pharma

Patients in Scotland with with advanced or unresectable hepatocellular carcinoma (HCC) will now be able to access Eisai and MSD’s …

News

NICE turns down Astellas’ Xtandi in prostate cancer

April 8, 2019
Research and Development, Sales and Marketing Astellas, Cancer, NHS, NICE, UK, pharma, prostate cancer

Astellas’ Xtandi (enzalutamide) has been rejected by UK medicines watchdog NICE for use on the NHS as a therapy for …

News
nhs_andrew_tatlow

NHS England threatened legal action against Oxford University hospitals trust

April 4, 2019
Medical Communications, Research and Development Hopsitals, NHS, NHS England, OUH, cancer screening, patients

NHS England threatened to sue Oxford University hospitals (OUH) NHS trust after they objected to the former’s controversial decision to …

News
nhs_andrew_tatlow

NHS gender pay gap has increased since last year

April 3, 2019
Research and Development NHS, NHS trusts, analysis, gender pay gap, salary

The gender pay gap has worsened in the NHS, according to analysis from The Guardian, which found the gender pay …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026